Evidence map›Paper›PMID 31692908›Full record

ArticleOncotarget2019

Hyperpolarized

David E Korenchan, Robert Bok, Renuka Sriram, Kristina Liu, Romelyn Delos Santos, Hecong Qin, Iryna Lobach, Natalie Korn, David M Wilson, John Kurhanewicz and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Role of pH Regulatory Proteins and Dysregulation of pH in Prostate Cancer.Reviews of physiology, biochemistry and pharmacology · 2022
    Article
  12. Article
  13. Review
  14. Cardiac pH-Imaging With Hyperpolarized MRI.Frontiers in cardiovascular medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

David E KorenchanDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Robert BokDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Renuka SriramDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Kristina LiuDepartment of Physical Chemistry, Technical University of Munich, Munich, Germany.
Romelyn Delos SantosDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Hecong QinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Iryna LobachDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Natalie KornDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
John KurhanewiczDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.
University of California, San Francisco · USTechnical University of Munich · DE

Funding

TR&D3: Open-Source Tools for Processing Hyperpolarized MR DataP41EB013598 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Daniel B Vigneron · 2011 to 2026
$19.9M
Ascorbate-based biomarkers for predicting radiation response in prostate cancerR01CA166766 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILSON, DAVID M · 2012 to 2016
$2.4M
Application of hyperpolarized 13C interstitial pH imaging to risk stratification in prostate cancerR21EB026012 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FLAVELL, ROBERT RICHARD · 2018 to 2020
$503k
NCI NIH HHS R01 CA166766NIBIB NIH HHS P41 EB013598NIBIB NIH HHS R21 EB026012
6 · The paper itself

Abstract

There is an unmet clinical need for new and robust imaging biomarkers to distinguish indolent from aggressive prostate cancer. Hallmarks of aggressive tumors such as a decrease in extracellular pH (pH

Indexed as

extracellular pHhyperpolarizationmetabolismMRIprostate cancer

Identifiers

PMID31692908
PMCPMC6817439
OpenAlexW2985576755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.